Literature DB >> 26545402

Partnership Status and Socioeconomic Factors in Relation to Health Behavior Changes after a Diagnosis of Ductal Carcinoma In Situ.

Sherrie Khadanga1, Susan G Lakoski2, Vicki Hart3, Brian L Sprague4, Yi Ba5, John M Hampton6, Stephen T Higgins7, Philip A Ades2, Polly A Newcomb8, Amy Trentham-Dietz9.   

Abstract

BACKGROUND: Change in health behaviors can occur among women newly diagnosed with ductal carcinoma in situ (DCIS). We sought to understand whether partnership status and socioeconomic status (SES) affected behavioral changes in body weight, physical activity, alcohol consumption, and smoking.
METHODS: The Wisconsin In Situ Cohort (WISC) study comprises 1,382 women diagnosed with DCIS with information on demographics, SES factors, and pre- and post-DCIS diagnosis health-related behaviors. Logistic regression models were used to determine the association between partnership status, education, and income with change in behavior variables.
RESULTS: Higher educational attainment was associated with lower likelihood of stopping physical activity [OR, 0.45; 95% confidence interval (CI), 0.32-0.63; college vs. high school degree], or starting to drink alcohol (OR, 0.34; 95% CI, 0.15-0.80). Results suggested that higher family income was associated with lower likelihood of gaining >5% body mass index (P = 0.07) or stopping physical activity (P = 0.09). Living with a partner was not strongly associated with behavior changes.
CONCLUSION: Higher educational attainment and higher income, but not living with a partner, were associated with positive health behaviors after a DCIS diagnosis. IMPACT: The associations between higher educational attainment and, to a lesser extent, higher income with positive health behaviors underscore the importance of considering SES when identifying those at risk for negative behavioral change after DCIS diagnosis. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 26545402      PMCID: PMC4713311          DOI: 10.1158/1055-9965.EPI-15-0726

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  31 in total

Review 1.  Ductal carcinoma in situ of the breast.

Authors:  Nicola L P Barnes; Jane L Ooi; John R Yarnold; Nigel J Bundred
Journal:  BMJ       Date:  2012-02-29

2.  Risk of subsequent invasive breast cancer after breast carcinoma in situ.

Authors:  F Wärnberg; J Yuen; L Holmberg
Journal:  Lancet       Date:  2000-02-26       Impact factor: 79.321

3.  A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancer.

Authors:  Ying Liu; Maria Pérez; Mario Schootman; Rebecca L Aft; William E Gillanders; Matthew J Ellis; Donna B Jeffe
Journal:  Breast Cancer Res Treat       Date:  2010-05-06       Impact factor: 4.872

4.  Physical activity levels after treatment for breast cancer: one-year follow-up.

Authors:  Nele Devoogdt; Marijke Van Kampen; Inge Geraerts; Tina Coremans; Steffen Fieuws; Johan Lefevre; Renaat Philippaerts; Steven Truijen; Patrick Neven; Marie-Rose Christiaens
Journal:  Breast Cancer Res Treat       Date:  2010-06-27       Impact factor: 4.872

5.  Physical activity behaviors in women with newly diagnosed ductal carcinoma-in-situ.

Authors:  Jennifer A Ligibel; Ann Partridge; Anita Giobbie-Hurder; Mehra Golshan; Karen Emmons; Eric P Winer
Journal:  Ann Surg Oncol       Date:  2008-10-24       Impact factor: 5.344

6.  Psychological distress and physical health in the year after diagnosis of DCIS or invasive breast cancer.

Authors:  Sophie Lauzier; Elizabeth Maunsell; Pascale Levesque; Myrto Mondor; Jean Robert; André Robidoux; Louise Provencher
Journal:  Breast Cancer Res Treat       Date:  2009-08-04       Impact factor: 4.872

7.  Validation of a combined comorbidity index.

Authors:  M Charlson; T P Szatrowski; J Peterson; J Gold
Journal:  J Clin Epidemiol       Date:  1994-11       Impact factor: 6.437

8.  Comparison of self-reported and measured height and weight.

Authors:  M Palta; R J Prineas; R Berman; P Hannan
Journal:  Am J Epidemiol       Date:  1982-02       Impact factor: 4.897

9.  Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study.

Authors:  Karen Barnett; Stewart W Mercer; Michael Norbury; Graham Watt; Sally Wyke; Bruce Guthrie
Journal:  Lancet       Date:  2012-05-10       Impact factor: 79.321

Review 10.  Managing patients with multimorbidity: systematic review of interventions in primary care and community settings.

Authors:  Susan M Smith; Hassan Soubhi; Martin Fortin; Catherine Hudon; Tom O'Dowd
Journal:  BMJ       Date:  2012-09-03
View more
  3 in total

1.  Characterizing risky alcohol use, cigarette smoking, e-cigarette use, and physical inactivity among cancer survivors in the USA-a cross-sectional study.

Authors:  Jiyeong Kim; Theresa H Keegan
Journal:  J Cancer Surviv       Date:  2022-08-14       Impact factor: 4.062

2.  The association between post-diagnosis health behaviors and long-term quality of life in survivors of ductal carcinoma in situ: a population-based longitudinal cohort study.

Authors:  Vicki Hart; Amy Trentham-Dietz; Amy Berkman; Mayo Fujii; Christopher Veal; John Hampton; Ronald E Gangnon; Polly A Newcomb; Susan C Gilchrist; Brian L Sprague
Journal:  Qual Life Res       Date:  2018-02-07       Impact factor: 4.147

3.  Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy.

Authors:  Antonio Di Meglio; Julie Havas; Arnauld S Gbenou; Elise Martin; Mayssam El-Mouhebb; Barbara Pistilli; Gwenn Menvielle; Agnes Dumas; Sibille Everhard; Anne-Laure Martin; Paul H Cottu; Florence Lerebours; Charles Coutant; Anne Lesur; Olivier Tredan; Patrick Soulie; Laurence Vanlemmens; Florence Joly; Suzette Delaloge; Patricia A Ganz; Fabrice André; Ann H Partridge; Lee W Jones; Stefan Michiels; Ines Vaz-Luis
Journal:  J Clin Oncol       Date:  2022-04-21       Impact factor: 50.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.